Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia

Blood

Volumn 116, Issue 19, 2010, Pages 3933-3943

  Csomós, Krisztián ^a   Német, István ^a   Fésüs, László ^a   Balajthy, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN 2; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; RETINOIC ACID; SUPEROXIDE;

ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL CYCLE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENOME; GRANULOCYTE FUNCTION; MICROARRAY ANALYSIS; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RNA INTERFERENCE;

EID: 78149461657     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-266064     Document Type: Article

References (42)

1. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549-550. (Pubitemid 8045927)
2. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature. 1990;347(6293):558-561. (Pubitemid 20341546)
3. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR α with a novel putative transcription factor, PML. Cell. 1991;66(4):663-674. (Pubitemid 121001702)
4. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 1981;57(6):1000-1004.
5. Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood. 1983;62(6):1211-1217.
6. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572.
7. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all transretinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712-2718. (Pubitemid 28469083)
8. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood. 2000;95(1):90-95. (Pubitemid 30017230)
9. Luesink M, Pennings JL, Wissink WM, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009;114(27):5512-5521.
10. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77(5):1080-1086.
11. Hu ZB, Ma W, Uphoff CC, Lanotte M, Drexler HG. Modulation of gene expression in the acute promyelocytic leukemia cell line NB4. Leukemia. 1993;7(11):1817-1823. (Pubitemid 23347301)
12. Legras S, Gunthert U, Stauder R, et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood. 1998;91(9):3401-3413. (Pubitemid 28193893)
13. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002;27(10):534-539. (Pubitemid 35279599)
14. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical study. Cell Tissue Res. 1989;255(1):215-224. (Pubitemid 19017924)
15. Piacentini M, Farrace MG, Piredda L, et al. Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress. J Neurochem. 2002;81(5):1061-1072. (Pubitemid 34809289)
16. Balajthy Z, Csomos K, Vamosi G, Szanto A, Lanotte M, Fesus L. Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood. 2006;108(6):2045-2054. (Pubitemid 44395020)
17. Kim SY. New target against inflammatory diseases: transglutaminase 2. Arch Immunol Ther Exp (Warsz). 2004;52(5):332-337. (Pubitemid 39627939)
18. Schiffmann E, Geetha V, Pencev D, et al. Adherence and regulation of leukotaxis. Agents Actions Suppl. 1983;12:106-120.
19. Murtaugh MP, Arend WP, Davies PJ. Induction of tissue transglutaminase in human peripheral blood monocytes. J Exp Med. 1984;159(1):114-125. (Pubitemid 14182820)
20. Gentile V, Thomazy V, Piacentini M, Fesus L, Davies PJ. Expression of tissue transglutaminase in Balb-C 3T3 fibroblasts: effects on cellular morphology and adhesion. J Cell Biol. 1992;119(2):463-474.
21. Szondy Z, Sarang Z, Molnar P, et al. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci U S A. 2003;100(13):7812-7817. (Pubitemid 36760052)
22. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci. 2001;114(Pt 16):2989-3000.
23. Balklava Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M. Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem. 2002;277(19):16567- 16575. (Pubitemid 34967673)
24. Seiving B, Ohlsson K, Linder C, Stenberg P. Transglutaminase differentiation during maturation of human blood monocytes to macrophages. Eur J Haematol. 1991;46(5):263-271.
25. Toth B, Garabuczi E, Sarang Z, et al. Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol. 2009;182(4):2084-2092.
26. Tatsukawa H, Fukaya Y, Frampton G, et al. Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology. 2009;136(5):1783-1795.
27. Oliverio S, Amendola A, Di Sano F, et al. Tissue transglutaminase- dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol Cell Biol. 1997;17(10):6040-6048. (Pubitemid 27411112)
28. Mishra S, Melino G, Murphy LJ. Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein. J Biol Chem. 2007;282(25):18108-18115. (Pubitemid 47100203)
29. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem. 2002;277(23):20127-20130. (Pubitemid 34967301)
30. Park KC, Chung KC, Kim YS, Lee J, Joh TH, Kim SY. Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia. Biochem Biophys Res Commun. 2004;323(3):1055-1062. (Pubitemid 39243425)
31. Kim SY. Transglutaminase 2 in inflammation. Front Biosci. 2006;11:3026-3035.
32. Yang L, Zhao H, Li SW, et al. Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells. J Mol Diagn. 2003;5(4):212-221. (Pubitemid 37407444)
33. Zheng PZ, Wang KK, Zhang QY, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/ apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005;102(21):7653-7658.
34. Alon R, Feigelson SW, Manevich E, et al. alpha4beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the α4-cytoplasmic domain. J Cell Biol. 2005;171(6):1073-1084.
35. Reutershan J, Stockton R, Zarbock A, et al. Blocking p21-activated kinase reduces lipopolysaccharide-induced acute lung injury by preventing polymorphonuclear leukocyte infiltration. Am J Respir Crit Care Med. 2007;175(10):1027-1035. (Pubitemid 46741754)
36. Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J. 2005;19(3):467-469. (Pubitemid 40316552)
37. Raquil MA, Anceriz N, Rouleau P, Tessier PA. Blockade of antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the alveoli in streptococcal pneumonia. J Immunol. 2008;180(5):3366-3374.
38. Suh GY, Ham HS, Lee SH, et al. A Peptide with antitransglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice. Exp Lung Res. 2006;32(1-2):43-53.
39. Falasca L, Farrace MG, Rinaldi A, Tuosto L, Melino G, Piacentini M. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J Immunol. 2008;180(4):2616-2624.
40. Hsu HC, Tsai WH, Chen PG, Hsu ML, Ho CK, Wang SY. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells. Eur J Haematol. 1999;63(1):11-18.
41. Tsai WH, Shih CH, Lin CC, Ho CK, Hsu FC, Hsu HC. Monocyte chemotactic protein-1 in the migration of differentiated leukaemic cells toward alveolar epithelial cells. Eur Respir J. 2008;31(5):957-962.
42. Larson RS, Tallman MS. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol. 2003;16(3):453-461. (Pubitemid 37080607)